MEI Pharma, Inc.’s PI3K inhibitor zandelisib faces a longer road to the market than the company anticipated as the US Food and Drug Administration has adopted a more cautious stance on the long-troubled class and discouraged the company from filing for accelerated approval based on Phase II data. But given the zandelisib’s favorable toxicity profile relative to its peers, that longer road does not mean it is doomed, though it will have to meet a high efficacy bar to be competitive.
Despite FDA Setback, MEI’s Zandelisib Could Still Break PI3K Curse
Drug Faces Longer Path To Market
MEI/Kyowa Kirin will no longer seek accelerated approval based on a single-arm study as the FDA is calling for Phase III data due to growing conservatism regarding the PI3K class.
More from Strategy
• By
The US president's most recent comments suggest tariffs on pharma are imminent and Ireland has the most to lose.
• By
As drugmakers update investors on first quarter financial performance, uncertainty around global trade and US regulatory oversight is likely to dominate discussions.
• By
Faced with Trump’s hostile tariff moves, the UK aims to speed up clinical trial start times to support its pharma sector and invest £600m in a new health data research service.
• By
The biotech has rejected a takeover bid from Nordic Capital but a sale to private equity could be a solution to the public market's continued reluctance to adequately value PureTech’s hub-and-spoke business model.
More from Business
• By
The biotech has rejected a takeover bid from Nordic Capital but a sale to private equity could be a solution to the public market's continued reluctance to adequately value PureTech’s hub-and-spoke business model.
• By
There were six biopharma initial public offerings on Western stock exchanges, including five in the US, during the first quarter, but plunging stock values could halt further IPOs.
• By
Sector-specific tariffs, including on pharmaceuticals, could be announced as early as this week.